It goes both ways. The issue with papers that don't get retracted and investigators even being threatened for their work seems a little bit bigger.

And no, it still needs a lot more than being marketed. It's an open beta in a test namespace. There is a lot of organizational stuff still missing, integrations, interoperability, other more or less important features. It's been in the making for a decade, no need to rush anything and actively market an unfinished product.